First time available for research use

PD-1-antibody

Nivolumab antibody from Opdivo®

Therapeutic PD-1-antibody from the original Opdivo® commercial drug targeting the PD-1-antigen, also referred to as Opdivo® or nivolumab antibody. Research-relevant quantities are available as licence-free consumable in aliquoted or diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments, biosimilar developers can order different batches at the same time.

Choose your antibody
pd-1-antibody-nivolumab
Easy Access

Easy Access

Easy to order as license-free research consumable
Multiple batches

Multiple batches

Up to 10 batches of original drugs for examining batch-to-batch variations
Reduce costs

Reduce costs

Up to 80% less compared to the original pharmaceutical price
Prompt delivery

Prompt delivery

Shipment within days worldwide according to GDP-standards
Documented origin

Documented origin

Information on batch, registration number, expiry date, GDP-compliant pedigree

What our clients say

Nivolumab / Opdivo

Product Reference

Drug nameOpdivo®
INNNivolumab
API typeNivolumab is produced in Chinese hamster ovary cells by recombinant DNA technology
Pharmacotherapeutic group
Antineoplastic agents, monoclonal antibodies
ATC code
L01XC17
Target of antibody
PD-1; Synonyms: CD279, PD1, SLEB2, hPD-1, hPD-l, Ly101, Pdc1
General function
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody (HuMAb), which binds to the programmed death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. Engagement of PD-1 with the ligands PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment, results in inhibition of T-cell proliferation and cytokine secretion. Nivolumab potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands. In syngeneic mouse models, blocking PD-1 activity resulted in decreased tumour growth.
Combined nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) mediated inhibition results in improved anti-tumour responses in metastatic melanoma. In murine syngeneic tumour models, dual blockade of PD-1 and CTLA-4 resulted in synergistic anti-tumour activity.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)
Original license holder
Marketing authorisation numbers
EU/1/15/1014/001 - 002
Marketing authorisation holder
Bristol-Myers Squibb Pharma EEIG
Uxbridge Business Park
Sanderson Road
Uxbridge UB8 1DH
United Kingdom
Name of the manufacturer of the biological active substance
Bristol-Myers Squibb Company
6000 Thompson Road
East Syracuse, New York 13057
USA

Lonza Biologics, Inc.
101 International Drive
Portsmouth, New Hampshire 03801
USA
Samsung Biologics Co. Ltd.
125, Cheomdan-daero
Yeonsu-gu, Incheon, 21987
Korea
Name and address of the manufacturer(s) responsible for batch releaseBristol-Myers Squibb S.r.l.
Loc. Fontana del Ceraso
03012 Anagni (FR)
Italy
Max shelf life
24 months
Storage conditions
2°C – 8°C
List of excipients
Sodium citrate dihydrate